Has Divya Manohara received payments from drug or device companies?

Yes. Drug and device makers reported $2,715 in general payments to Divya Manohara across 129 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Divya Manohara did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Divya Manohara come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Divya Manohara

Internal Medicine · San Luis Obispo, CANPI 1477086122

Payments from drug & device makers

$2,715in general payments, 2019–2025

Across 129 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$503
GSK$463
Novo Nordisk$382
AstraZeneca$343
AbbVie$291
Boehringer Ingelheim$200
plus $533 from 13 others

What the payments were for

Food & beverage$2,715100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	21	$503
GSK	24	$463
Novo Nordisk	17	$382
AstraZeneca	18	$343
AbbVie	14	$291
Boehringer Ingelheim	9	$200
Pfizer	5	$103
Lilly USA, LLC	3	$67
Merck	2	$47
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$45
Kyowa Kirin, Inc.	2	$45
Radius Health, Inc.	2	$40
CSL Behring	2	$38
Exact Sciences	2	$36
Bayer	2	$33
Aimmune Therapeutics, Inc.	1	$27
Novartis	1	$21
Teva Pharmaceuticals USA, Inc.	1	$18
Sanofi-aventis U.S. LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Ozempic$123
EVENITY$114

How this compares

$2,715 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	175	$194,077
OzempicSemaglutide	97	$103,108
XareltoRivaroxaban	70	$71,669
JardianceEmpagliflozin	50	$66,762
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	52	$55,938
ProliaDenosumab	19	$31,764
JanuviaSitagliptin Phosphate	23	$28,132
RybelsusSemaglutide	15	$27,045
TrulicityDulaglutide	24	$23,836
LinzessLinaclotide	36	$21,410
MounjaroTirzepatide	16	$16,893
Spiriva RespimatTiotropium Bromide	11	$13,326
MyrbetriqMirabegron	11	$12,210
Levothyroxine Sodium	541	$10,120
Atorvastatin Calcium	613	$7,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis, Premarin	$103	$197,162188 claims
Novo NordiskOzempic, Rybelsus	$382	$130,154112 claims
Boehringer IngelheimJardiance, Spiriva Respimat	$200	$80,08961 claims
GSKTrelegy Ellipta, Breo Ellipta	$463	$62,05368 claims
Lilly USA, LLCTrulicity, Mounjaro	$67	$40,72940 claims
AmgenProlia	$503	$31,76419 claims
MerckJanuvia	$47	$28,13223 claims
AbbVieLinzess, Synthroid	$291	$23,65354 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Luis Obispo

Andrew ChengSouth San Francisco$55.1M
Joel NeutelTustin$34.9M
Donald BrandonSan Diego$34M
William TownerLos Angeles$27.4M
Rahul AggarwalSan Francisco$24M
Masoud AzizadNorthridge$21.1M
Helen StaceyWalnut Creek$20.4M
Rohit Loombala Jolla$15.1M
Zeid KayaliColton$14.2M
Alexandra DrakakiSanta Monica$14.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →